Pharma Marketing News Vol. 8, #10: Nov/Dec 2009
Welcome to the NOV/DEC 2009 issue of Pharma Marketing News.
Pharma Marketing News Vol. 8, #10: Nov/Dec 2009
Welcome to the NOV/DEC 2009 issue of Pharma Marketing News.
Consequences of Direct-to-Consumer Advertising: Links to Higher Prices and Less Competition
This article focuses on a new study that suggests drug price increases are engineered to cover the costs of Direct-to-Consumer Advertising (DTCA). Drug price trend data from AARP, AHRQ, and prescription drug consumer price index (CPI) are presented. Also, what's the link between DTCA and competition?
Search Advertising Options for Pharma: What to Do While Waiting for Those Guidelines
In this article, Julie Batten, eMarketing Manager at Klick Pharma discusses pharma's options for search marketing in this period between the FDA public hearing and when the much anticipated draft and final guidance on the issue is published.
A Few Things I Learned at FDA’s Social Media Hearing: What’s Next is What...
This article presents key takeaways from the FDA hearing, a synopsis of the presentations made by John Mack, Publisher, Pharma Marketing News, at the hearing, a review of Ignite Health's study regarding effectiveness of sponsored links, and the next steps in the process of issuing guidance.
Pharma’s Image Conundrum: Building Brand Loyalty and Consumer Confidence
In this guest article, Carla Stratfold, CEO at OnRequest Images, presents several key learnings and best practices that pharmas can follow when building brand and consumer loyalty.
Pharma Marketing News Vol. 8, #9
Welcome to the October 2009 issue of Pharma Marketing News.
Pharma Marketing News Vol. 8, #9
Welcome to the October 2009 issue of Pharma Marketing News.
Social Media Adverse Event Reporting Safe Harbors: It’s Time for FDA to Open Up...
This article presents ideas for regulatory 'safe harbors' under which pharmaceutical companies would be relieved of the responsibility of monitoring social media for adverse events. Includes a detailed summary of responses to the survey 'FDA Regulation of Drug & Device Promotion via the Internet & Social Media' regarding social media adverse event monitoring, processing, challenges, and uncertainties.
Pharmaceutical Market Access 2010: Strategic Developments Impacting the US, EU, and Emerging Markets
Future revenue growth in the US and EU will be limited as the EU wrestles with cost effectiveness and the US debates healthcare reforms. Meanwhile, pharma and biotech companies are looking to emerging market opportunities in Brazil, Russia, India, and China (i.e., BRIC) to drive future business. What does this all mean for patients, physicians, payers, and pharmaceutical/biotech manufacturers? This article addresses that question.
